跳至主要内容

2020.4 NDA/BLA Inspection Schedule by CFDI for NMPA

 April 2020 NDA/BLA Inspection Schedule by CFDI for NMPA:

No.Acceptance numberCompanyProducts
1CXSS1900005 Xinjiang Deyuan BioengineeringHuman Immunnglnhlobulin (pH4) for Intravenous Injection
2CXSS1700033 Shanxi Kangbao BiologicalHuman coagulation factor Ⅷ 
3CYHS1900202 Chongqing Huapont PharmAminosalicylate  Enteric-CoatedGranules
4CXHS1800035 Yichang Humanwell PharmaRamimazolam Besilate for Injection 
5CXSS1800029 Heibei Daan Pharma Human Immunnglnhlobulin (pH4) for Intravenous Injection
6Y20190000075 Chongqing Huapont Kaisheng PharmAminosalicylate 
7CYSB1800230 Beijing Kawin Technology Recombinant Human Interferon α2b Injection 
8CYSB1800229 Beijing Kawin Technology Recombinant Human Interferon α2b Injection
9CYSB1800228 Beijing Kawin TechnologyRecombinant Human Interferon α2b Injection
10CYSB1800231 Beijing Kawin TechnologyRecombinant Human Interferon α2b Vaginal Effervescent Tablets
11CXSS1900029 Heibei Daan Pharma Human Prothrombin Complex 
12CXSS1800007 China Biologic Products Human coagulation factor IX
13Y20180000992 Nanjing Chia Tai Tianqing Pharma Clopidogrel Hydrogen Sulphate
14CXSS1800007 China Biologic Products Human coagulation factor IX 
15CYHS1800138 HEC Pharm Linagliptin and Metformin Hydrochloride Tablets(Ⅲ) 
16CXHS1800034 Yichang Humanwell PharmaRamimazolam Besilate
17CYHS1800136 HEC Pharm Linagliptin and Metformin Hydrochloride Tablets(Ⅰ) 
18CYHS1800137 HEC Pharm Linagliptin and Metformin Hydrochloride Tablets(Ⅱ) 

评论